FMC (FMC) has drawn attention after reporting annual revenue of US$3.47b alongside a net loss of US$2.20b. This has prompted investors to reassess how the agricultural sciences group is currently being valued.
See our latest analysis for FMC.
Despite the headline net loss, FMC’s recent share price performance has been firmer, with a 12.8% 1 month share price return and a 15.5% 3 month share price return. However, the 1 year total shareholder return of 61.4% remains deeply negative.
If you are reassessing FMC and want to broaden your watchlist, this is a good moment to look at other materials names using the 8 top copper producer stocks
With FMC trading at US$15.66 and an estimated intrinsic value gap of about 26%, the key question for you is whether this reflects genuine undervaluation or whether the market already has future growth fully priced in.
Most Popular Narrative: 13.6% Undervalued
FMC’s most followed valuation narrative places fair value at about $18.12 per share, compared with the last close at $15.66. This frames the stock as modestly discounted while still pricing in a recovery story.
Ongoing cost transformation, including lower manufacturing costs for key products like Rynaxypyr and benefits from 2024-2025 restructuring, creates durable COGS reductions and improved fixed cost absorption, serving as a catalyst for sustainable EBITDA and net margin improvement. The shift away from direct commercial operations in India to a lower-risk B2B supply model frees up cash for debt reduction, enhances the balance sheet, and enables redeployment of capital toward high-value innovation and growth portfolios, which is expected to have a positive impact on net earnings over the long term.
Want to see what kind of revenue rebuild, margin reset, and earnings ramp need to happen for that valuation to hold? The full narrative lays out detailed growth, profitability, and discount rate assumptions that connect today’s share price to that fair value target.
Result: Fair Value of $18.12 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there are still clear risks, including ongoing regulatory scrutiny and pricing pressure from generics, that could challenge the hoped-for margin repair story.
Find out about the key risks to this FMC narrative.
Next Steps
Mixed story so far? With both concerns and optimism in play, this is a moment to move quickly, review the details, and weigh the 3 key rewards and 2 important warning signs.
Looking for more investment ideas?
If you stop with just one name, you risk missing other opportunities that might suit your goals better. Use screeners to widen your options intelligently.
- Spot potential mispricing early by checking out 61 high quality undervalued stocks that pair stronger fundamentals with room for sentiment to catch up.
- Strengthen your income watchlist by scanning 12 dividend fortresses that focus on higher yields with support from current metrics.
- Prioritise resilience by reviewing 69 resilient stocks with low risk scores designed to highlight companies with lower overall risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com